Sign in

You're signed outSign in or to get full access.

Charles Ndiaye

Charles Ndiaye

Biotech Equity Research Associate at Stifel Financial Corp.

Boston, MA, US

Charles Ndiaye is a Biotech Equity Research Associate at Stifel Financial Corp., specializing in the analysis of biotechnology companies with a focus on delivering strategic insights for investment decisions. He supports coverage of innovative biotech firms, contributing to research on companies developing novel therapeutics and technologies, though detailed performance metrics and specific rankings are not publicly disclosed. Ndiaye began his equity research career at Stifel and has continued to build industry expertise in the biotechnology sector as of 2024. He maintains professional credentials as a registered representative, holding FINRA Series 7 and Series 63 licenses.

Charles Ndiaye's questions to Kymera Therapeutics (KYMR) leadership

Question · Q4 2025

Charles Ndiaye asked about the gating factors for initiating new Phase II studies for KT-621 beyond atopic dermatitis (AD) and asthma.

Answer

CEO Nello Mainolfi clarified that Kymera's strategy for KT-621 is to leverage the ongoing Phase IIb AD and asthma studies to support future registrational (Phase III) trials in other dermatologic and respiratory indications, respectively. He stated that the company does not plan to initiate new Phase II studies, aiming for all subsequent studies to be registrational.

Ask follow-up questions

Fintool

Fintool can predict Kymera Therapeutics logo KYMR's earnings beat/miss a week before the call

Question · Q4 2025

Charles Ndiaye asked about the gating factors for initiating Phase 2 studies for KT-621 in indications beyond atopic dermatitis and asthma.

Answer

Nello Mainolfi, Founder, President, and CEO, clarified that Kymera's strategy is to leverage the ongoing dose-ranging Phase 2b studies in AD and asthma to support late-stage development in other dermatologic and respiratory indications, respectively. He stated that they do not plan to start new Phase 2 studies, and any future new studies are expected to be registrational (Phase 3).

Ask follow-up questions

Fintool

Fintool can write a report on Kymera Therapeutics logo KYMR's next earnings in your company's style and formatting

Charles Ndiaye's questions to Travere Therapeutics (TVTX) leadership

Question · Q3 2024

Charles Ndiaye from Stifel Financial Corp. asked about the company's current expectations for the Loss of Exclusivity (LOE) timeline for sparsentan in IgAN and how those expectations might change.

Answer

President and CEO Dr. Eric Dube stated that the company's current base planning assumption for LOE is into 2033. He also noted that the full approval in IgAN granted an additional term of orphan drug exclusivity through September 2031, providing another layer of protection.

Ask follow-up questions

Fintool

Fintool can predict Travere Therapeutics logo TVTX's earnings beat/miss a week before the call